<DOC>
	<DOCNO>NCT00839007</DOCNO>
	<brief_summary>The primary objective study assess safety tolerability IV administration CD-NP dose relationship CD-NP improvement clinical symptom renal function ADHF patient .</brief_summary>
	<brief_title>Study Assess Safety Efficacy CD-NP Treatment Patients With Acute Decompensated Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Key 1 . Hospitalized acute decompensated heart failure . 2 . Systolic blood pressure ≥ 115 mmHg ≤ 200 mmHg , diastolic blood pressure ≥ 60 mmHg ≤ 110 mmHg screen 3 . Renally compromise . 4 . Female patient must postmenopausal surgically sterile . Key 1 . Acute suspect acute myocardial infarction ( AMI ) troponin level &gt; 3X upper limit normal institution 's local laboratory 2 . Cardiogenic shock 3 . Evidence uncorrected volume sodium depletion clinical condition would predispose patient adverse event 4 . Clinically significant aortic mitral valve stenosis 5 . Temperature &gt; 38°C ( oral equivalent ) , sepsis active infection require IV antimicrobial treatment 6 . ADHF due significant arrhythmias 7 . Severe renal failure define creatinine clearance &lt; 30 mL/min 8 . Current planned ultrafiltration , hemofiltration , dialysis 9 . Significant pulmonary disease 10 . Major neurologic event , include cerebrovascular event prior 60 day . 11 . Acute myocarditis hypertrophic obstructive , restrictive , constrictive cardiomyopathy ( include restrictive mitral filling pattern ) 12 . Known hypersensitivity allergy natriuretic peptide component , nesiritide , natriuretic peptide related compound</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>ADHF</keyword>
	<keyword>AHF</keyword>
	<keyword>HF</keyword>
</DOC>